Dabigatran-related serious medication errors: an analysis using data from VigiBase

ConclusionBased on the analysis of reports in VigiBase, serious MEs related to dabigatran mainly occurred during prescription and administration. Although the incidence of MEs with clinical consequences in the use of dabigatran cannot be determined, attention should be paid to selection of the appropriate dose to a right patient in the prescription, and to patient compliance and storage in drug administration. The patient harm mainly manifested itself as bleeding or ischemia including fatal outcome in rare patients.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research